Alnylam Pharmaceuticals Inc (ALNY) — Strategic Asset Allocation Index
Alnylam Pharmaceuticals Inc (ALNY) has a Strategic Asset Allocation Index of 415.9% as of June 2022. Strategic assets (PP&E of $732.12 Million plus long-term investments of $-) total $732.12 Million, measured against net assets of $176.04 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Alnylam Pharmaceuticals Inc Strategic Asset Allocation Index (2004–2021)
This chart shows how Alnylam Pharmaceuticals Inc's Strategic Asset Allocation Index has evolved across 18 annual periods from 2004 to 2021. As of June 2022, the index stands at 415.9%, representing strategic assets of $732.12 Million against net assets of $176.04 Million USD. Explore cash flow conversion of Alnylam Pharmaceuticals Inc to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Alnylam Pharmaceuticals Inc (2004–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for Alnylam Pharmaceuticals Inc from 2004 to 2021, covering 18 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see ALNY company net worth.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 85.3% | $501.96 Million | $501.96 Million | $- | $588.20 Million | ▲ +39.6 pp |
| 2020 | 45.8% | $465.03 Million | $465.03 Million | $- | $1.02 Billion | ▲ +15.2 pp |
| 2019 | 30.6% | $440.00 Million | $425.18 Million | $14.82 Million | $1.44 Billion | ▲ +6.0 pp |
| 2018 | 24.6% | $320.66 Million | $320.66 Million | $0.00 | $1.30 Billion | ▲ +13.5 pp |
| 2017 | 11.1% | $195.82 Million | $181.90 Million | $13.92 Million | $1.77 Billion | ▼ -36.7 pp |
| 2016 | 47.7% | $439.37 Million | $114.57 Million | $324.80 Million | $920.22 Million | ▲ +25.6 pp |
| 2015 | 22.1% | $279.65 Million | $27.81 Million | $251.84 Million | $1.26 Billion | ▼ -10.1 pp |
| 2014 | 32.2% | $301.56 Million | $21.74 Million | $279.82 Million | $936.27 Million | ▼ -29.4 pp |
| 2013 | 61.6% | $166.50 Million | $16.45 Million | $150.05 Million | $270.35 Million | ▼ -30.3 pp |
| 2012 | 91.9% | $123.22 Million | $19.80 Million | $103.42 Million | $134.05 Million | ▼ -17.9 pp |
| 2011 | 109.8% | $129.61 Million | $14.64 Million | $114.97 Million | $118.00 Million | ▲ +22.2 pp |
| 2010 | 87.6% | $138.68 Million | $18.29 Million | $120.39 Million | $158.23 Million | ▲ +77.3 pp |
| 2009 | 10.3% | $18.32 Million | $18.32 Million | $- | $177.97 Million | ▲ +0.8 pp |
| 2008 | 9.5% | $19.19 Million | $19.19 Million | $- | $202.12 Million | ▲ +2.6 pp |
| 2007 | 6.9% | $13.81 Million | $13.81 Million | $- | $199.17 Million | ▲ +0.9 pp |
| 2006 | 6.1% | $12.17 Million | $12.17 Million | $- | $201.17 Million | ▼ -11.1 pp |
| 2005 | 17.1% | $10.58 Million | $10.58 Million | $- | $61.78 Million | ▼ -8.2 pp |
| 2004 | 25.3% | $11.69 Million | $11.69 Million | $- | $46.14 Million | — |